ArticleInfection and drug resistance2023
Characterisation of a Novel Hybrid IncFII
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- Genomic Insights Into Carbapenem-Resistant Klebsiella pneumoniae in Pediatric Bloodstream Infections in Zhejiang, China (2019-2024).Journal of clinical laboratory analysis · 2026Article
- Article
- Clinical risk factors and genomic characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Emergence of ST11Microbiology spectrum · 2025Article
- Mobile genetic elements inJournal of bacteriology · 2025Review
- Transcriptomic Insights into Adaptive Strategies ofInfection and drug resistance · 2025Article
- Epidemiological and biological characteristics of IncR plasmids as multihost antibiotic resistance carriers.Frontiers in microbiology · 2025Review
- The characterization of an IncN-IncR fusion plasmid co-harboring blaScientific reports · 2024Article
- Carbapenem-ResistantInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We aimed to characterize a novel Methods: Antimicrobial susceptibility was determined by the broth microdilution method. Plasmid size and localization were estimated using S1 nuclease pulsed-field gel electrophoresis (S1-PFGE) and Southern blotting. Plasmid transfer ability was evaluated by conjugation experiments. Whole genome sequencing (WGS) was performed using Illumina NovaSeq6000 and Oxford Nanopore MinION platforms. Genomic characteristics were analyzed using bioinformatics methods. Results: Strain ZY27320 was a multidrug-resistant (MDR) clinical ST11 Conclusion: This is the first report of a hybrid plasmid carrying both carbapenemase genes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.